Reference for the success rate and actual efficacy of HIV blocking tablets

Biktarvy tablets (Biktarvy) is a drug containing Bictegravir (Bictegravir)+ Tenofovir alafenamide (TAF) + Emtricitabine (FTC) is a three-in-one anti-HIV single-pill combination regimen. It is currently one of the most widely used first-line antiretroviral treatment (ART) drugs in the world with the highest success rate. Its core advantages lie in its strong virus suppression ability, good tolerance, and high genetic barrier, which means it is not easy to develop drug resistance, making its success rate particularly high among newly treated patients. Most patients can significantly reduce their viral load to undetectable levels within 4~12 weeks after taking the medication regularly.

Judging from clinical data, the viral suppression success rate of Bikern Prenol Tablets generally exceeds 95%. In many large-scale III studies, more than 90% of patients took 48 weeks, or even 96 The undetectable status of HIV RNA<50 copies/mL was still maintained after weeks. For first-time treatment patients, success rates can even approach 98% to 100%. This means that as long as they insist on taking medication on time every day, the vast majority of patients can stably achieve their viral suppression goals. In addition, for patients who switch from other regimens to Biktarvy , the efficacy is also stable, viral control is not affected, and the "undetectable" rate after switching is usually above 95% .

In actual experience and real-world (Real-world) data, Biktarvy ’s performance is equally impressive. Cohort studies in many countries have shown that patients are not only very easy to adhere to in daily clinical use (due to once a day, no food restrictions), but also have few side effects, the most common being mild gastrointestinal discomfort or short-term headache, which usually resolve on their own. After taking the drug, most patients have improved energy, steady increase in immune function (CD4), and improved quality of life, and rarely need to change the regimen due to intolerance. At the same time,Biktarvy has less impact on kidneys and bones than the older generation TDF solution, and is safer for high-risk groups.

Generally speaking, Bikeren Prenol Tablets (Bituvi) have a very high viral suppression success rate, excellent long-term stability and extensive real-world data support, and are currently the most highly recommended by international guidelines. HIV One of the first-line treatment options. As long as they insist on daily taking on time and reasonable follow-up, the vast majority of patients can achieve long-term virus-free detection, and the goal of "U=U" (Undetectable = Untransmittable, virus undetectable= no risk of sexual transmission) is also completely achievable. For patients who want high success rates and low side effects, Biktarvy is a very mature and reliable choice.

Reference:https://reference.medscape.com/